Zepzelca
(Lurbinectedin)ApprovedSmall molecule
Jazz PharmaceuticalsLurbinectedin is used to treat certain types of lung cancer and ovarian cancer that have not responded to other treatments. It works by damaging cancer cell DNA to stop the cancer from growing.[2] Zepzelca is currently approved and in use across 17 indications[4].[1]
Zepzelca is one of 420 small molecule programs targeting Small Cell Carcinoma. It is currently in Approved.
17
Indications
51
Total Trials
29
Active Trials
419
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zepzelca
Jazz PharmaceuticalsApproved
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer10 trials
Show 7 more trials
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Not yet recruiting·—·Phase 1/2·NCT07141771·100 enrolled
Lung Cancer3 trials
Ovarian Cancer2 trials
Leiomyosarcoma2 trials
29 more indications
Patients With Advanced Solid Tumors2 trials
Unresectable Solid Tumor2 trials
Ewing sarcoma2 trials
Solid Tumors1 trial
Immune Checkpoint Inhibition1 trial
Neuroendocrine Cancer1 trial
Malignant Pleural Mesothelioma1 trial
Cardiac Repolarization1 trial
Relapse1 trial
Treatment1 trial
Patients With Solid Tumors1 trial
Metastatic Colorectal Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Selected Advanced Solid Tumors1 trial
Gastrointestinal1 trial
Durvalumab1 trial
Small Cell Carcinoma1 trial
Advanced or Metastatic Solid Tumors1 trial
Efficacy and Safety1 trial
First Line Therapy1 trial
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Not yet recruiting·—·Phase 2·NCT06501976·9 enrolled
Tumors1 trial
Lurbinectedin in FET-Fused Tumors
Recruiting·—·Phase 1/2·NCT05918640·63 enrolled
Small Cell Lung Cancer ( SCLC )1 trial
Regulatory
FDA Approval Timeline[5]
Jun 15, 2020
ZEPZELCA
NDA NDA213702
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zepzelca drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Lurbinectedin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company